DELFI Diagnostics Supports Proposed Legislation to Allow CMS to Review New Blood-Based Screening Tests for Lung Cancer

BALTIMORE and PALO ALTO, Calif., Dec. 13, 2023 /PRNewswire-PRWeb/ — DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, today announced support for the recently introduced Lung Cancer Screening and Prevention Act (H.R….

Click here to view original post

Advertisement — Advertise with Biotech Networks